This review paper, published in the Journal of Zhejiang University (Medical Sciences), provides a comprehensive look at the rapidly evolving landscape of Antibody-Drug Conjugates (ADCs) for treating metastatic castration-resistant prostate cancer (mCRPC). As traditional therapies hit a wall of resistance, these "biological missiles" are being engineered to deliver high-potency payloads directly to tumor cells with increasing precision.
TL;DR
ADCs are emerging as a transformative precision medicine for advanced prostate cancer, moving beyond the limitations of traditional chemotherapy. This review highlights how next-generation ADCs—particularly those targeting PSMA and B7-H3—are overcoming the toxicity hurdles of earlier versions to show significant clinical promise.
What Problem Does This Paper Address?
Prostate cancer is a leading cause of death among men globally. While initial cases often respond well to androgen deprivation therapy (hormone therapy), the disease frequently progresses to a "castration-resistant" state (mCRPC). At this stage, the cancer becomes highly heterogeneous and resistant to standard treatments.
The challenge is twofold:
- Specificity: Traditional chemotherapy kills healthy cells along with cancerous ones, leading to severe side effects.
- Resistance: Tumors adapt to survive hormone-blocking drugs.
ADCs attempt to solve this by using a monoclonal antibody to find a specific "zip code" (an antigen) on the surface of a cancer cell, then releasing a toxic payload only after being swallowed by that cell.
Methods
As a review article, the authors synthesized data from over 40 clinical trials and preclinical studies. They categorized the current state of the field based on the molecular targets (antigens) being exploited:
- PSMA (Prostate-Specific Membrane Antigen): The most established target.
- B7-H3: An immune checkpoint molecule highly expressed in aggressive tumors.
- STEAP1, TROP2, and SLC44A4: Emerging targets showing varying degrees of success.
- Dual-Targeting: A novel approach using "bispecific" ADCs to hit two different antigens simultaneously.
The paper evaluates these based on their tripartite structure: the antibody (the seeker), the payload (the killer, often MMAE or topoisomerase inhibitors), and the linker (the glue that holds them together until they reach the target).
Datasets
The authors utilized data from the National Clinical Trials (NCT) database, specifically tracking 14 major ADC candidates (summarized in the paper's Table 1). Key trials mentioned include:
- NCT04662580: Evaluating the next-gen PSMA-targeted ADC, ARX517.
- NCT06925737: The first international Phase III trial for a B7-H3 ADC (ifinatamab deruxtecan).
- NCT03725761: Assessing Sacituzumab govitecan (TROP2-targeted).
Key Insights and Ideas
- The Linker is the Secret Sauce: Early ADCs like MLN2704 failed because their linkers were "leaky," releasing the toxic payload into the bloodstream and causing neurotoxicity. Newer candidates like ARX517 use non-cleavable, site-specific linkers that are much more stable, leading to better safety profiles.
- B7-H3 as the "Rising Star": While PSMA is the gold standard, its expression can be low in some patients. B7-H3 expression remains high even in PSMA-low tumors and is often upregulated in treatment-resistant cells, making it a critical alternative target.
- Combating Heterogeneity with Dual-Targeting: Because not every cell in a tumor expresses the same antigen, "dual-target" ADCs (like ABBV-969, which hits both PSMA and STEAP1) are being developed to ensure no cancer cell is left behind.
- The Bystander Effect: Some payloads can cross cell membranes after the initial target cell dies, killing neighboring cancer cells that might not even express the target antigen. This is crucial for treating "patchy" tumors.
Key Results
- ARX517 (PSMA): In Phase I trials, patients receiving a 2.0 mg/kg dose saw PSA (Prostate-Specific Antigen) reductions of over 50%, with some exceeding 90%, without the severe dose-limiting toxicities seen in older drugs.
- MGC018 (B7-H3): Demonstrated a 17.2% PSA response rate in early trials for advanced solid tumors.
- Ifinatamab Deruxtecan: This B7-H3-targeted ADC has shown such strong preliminary data that it moved into a Phase III clinical trial in May 2025.
- Failures provide lessons: Tisotumab vedotin (targeting Tissue Factor) showed no significant response in mCRPC, suggesting that not every high-expression antigen is a viable therapeutic target for this specific cancer.
Limitations and Future Work
Despite the excitement, several hurdles remain:
- Antigen Loss: Tumors can "hide" by stopping the expression of the target antigen (e.g., TROP2 loss), leading to drug resistance.
- The "Cold" Tumor Problem: Prostate cancer is often immunologically "cold," meaning it doesn't attract immune cells easily. Future work is looking at combining ADCs with Immune Checkpoint Inhibitors (ICIs) to "heat up" the tumor and improve outcomes.
- Optimal DAR: Finding the perfect Drug-to-Antibody Ratio (DAR) is a balancing act; too high can make the ADC unstable, while too low makes it ineffective.
The authors conclude that while no ADC is currently FDA-approved specifically for prostate cancer, the transition to Phase III trials for B7-H3 targets suggests a breakthrough is on the horizon.
Summary updated